Recent Press Releases

EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion

TARRYTOWN, N.Y., June 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval...

BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin...

UK Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the C

Veracyte Announces National Network Agreement with Aetna

SOUTH SAN FRANCISCO, Calif., June 25, 2015 /PRNewswire/ -- 

Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

Lilly Diabetes donation helps 21 students attend college through Tomorrow's Leaders Scholarships

ROLLING MEADOWS, Ill. and

Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham

Complaint seeks permanent injunctive relief to prevent overcharges and damages, and bring generic Gleevec to market BOSTON – A class-action lawsuit filed against Novartis alleges that the...

Novartis statement on Gleevec patent lawsuit

"We believe these claims are unsubstantiated. The patents covering Gleevec remain legally in force and are covered by a statutory presumption of validity. The patents are clearly directed to...

FDA Drug Safety Communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD

The U.S. Food and Drug Administration (FDA) is warning that permanent loss of skin color may occur with use of the Daytrana patch (methylphenidate transdermal system) for Attention Deficit...

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to...

U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines

- GSK's BEXSERO® included in Category B recommendation by the Advisory Committee on Immunization Practices (ACIP)

PHILADELPHIA,

Reimbursement Uncertainties Trouble Life Sciences Companies – BDO Report

June 2015 Amanda Chun Bliss Integrated Communication (212) 584-5482 amanda@blissintegrated.com CHICAGO – June 15, 2015 – For many years, the success of life sciences companies relied...

FDA approves new antiplatelet drug used during heart procedure

FDA approves new antiplatelet drug used during heart procedure June 22, 2015 The U.S. Food and Drug Administration today approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents...

The Medicines Company Announces FDA Approval of KENGREAL (cangrelor) as an Adjunct to Percutaneous Coronary Intervention (PCI) for Reducing Thrombotic Events

The Medicines Company Announces FDA Approval of KENGREAL (cangrelor) as an Adjunct to Percutaneous Coronary Intervention (PCI) for Reducing Thrombotic Events Novel intravenous antiplatelet agent adds...

Eisai Announces FDA Approval of FYCOMPA® (perampanel) CIII for Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures in Patients with Epilepsy Age 12 and Older

WOODCLIFF LAKE, N.J., June 22, 2015 /PRNewswire/ -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in...

Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714 at 16th International Coeliac Disease Symposium

Oral Presentation to Highlight Rationale for the Study of AMG 714 in the Treatment of Celiac and Refractory Celiac Disease

LEBANON, N.J.<

CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology

Encouraging Subgroup Findings Are Basis for New Phase III Trial

INDIANAPOLIS, June 19, 2015 /PRNewsw

Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine

Patients Experienced Sustained Reductions in Monthly Migraine Days and Consistent Safety Profile From Blinded Phase at 52 Weeks

THOUSAND

Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care

Met Secondary Endpoint of Overall Survival in Wild-Type RAS Metastatic Colorectal Cancer THOUSAND OAKS, Calif., June 18, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that a Phase 3 study...

CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology

CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology INDIANAPOLIS, June 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that The Lancet...

Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.

JERUSALEM, Jun 19, 2015 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (nyse and tase:TEVA) today announced that it has completed the purchase of 4.61 percent of all outstanding shares of...